The debate over single-payer healthcare in America is dense with objections — some grounded in legitimate evidence, some reflecting genuine values conflicts, and some that collapse quickly when examined against the data. This piece addresses the five most common arguments against single-payer, a major procedural objection that deserves its own treatment, the most frequently proposed alternative, and the argument that the US government already operates healthcare at scale. Each is presented in its strongest form before the evidence is examined.
Objection 1: “It Will Raise My Taxes”
This is the most common objection and, presented in isolation, the most incomplete. It focuses on one side of the ledger while ignoring the other.
The full question is not whether taxes would increase. Under most single-payer financing proposals they would, for most Americans. The question is whether taxes would increase by more or less than the premiums, deductibles, copays, and out-of-pocket costs they replace.
The Sanders Medicare for All Act proposes a 4% income-based premium in place of private premiums. For a family of four earning $50,000, that works out to $844 per year. The average worker contribution toward family employer coverage in 2025 was $6,850 per year, not counting deductibles or out-of-pocket costs. The net savings for that family would be substantial.
An analysis by Citizens for Tax Justice found that middle-class families would see after-tax income increase by approximately $3,240 per year under Medicare for All. A RAND/JAMA study found that the lowest-income households would see their healthcare burden drop from 27% of compensation to 15%. The highest-income households would see their share rise from 27% to 31%.
The objection is legitimate when directed at high earners, for whom the tax increase may genuinely exceed current premium costs. It is misleading when presented as a universal outcome. For most working families the math runs in the opposite direction. The honest version of this objection requires specifying whose taxes and comparing the full picture, not the tax line alone.
Verdict: Partially valid when applied to the highest-income households. Misleading as a general claim without full cost comparison.
Objection 2: “You’ll Wait Forever to See a Doctor”
Wait times are a real feature of some universal healthcare systems, most notably Canada and the United Kingdom. Canadian patients wait an average of 21.2 weeks from GP referral to specialist treatment. That is a documented and significant figure.
The context that this objection typically omits is substantial, however.
First, the wait time problem in Canada and the UK is not an inherent feature of single-payer systems. Taiwan, Germany, France, and Australia all operate under universal or single-payer frameworks and do not have comparable wait time problems. The research consistently identifies underfunding and insufficient provider capacity — political choices — as the cause of long waits, not the payment model itself.
Second, the comparison to the US baseline is incomplete when it ignores the Americans who cannot access care at all because they cannot afford it. Eighty-five million Americans are currently uninsured or underinsured. An uninsured patient with a needed specialist referral does not have a 21-week wait. They have no appointment. That outcome is worse by any measure.
Third, wait times in the US are already substantial in many specialties and in many geographic areas, driven by provider concentration in urban centers and the administrative burden that reduces the time physicians spend seeing patients.
Verdict: The wait time concern is real and documented for specific countries. It is not a universal feature of single-payer systems. It is a function of funding and capacity decisions that are separable from the payment model. The comparison is also incomplete without accounting for the Americans currently waiting indefinitely due to inability to pay.
Objection 3: “The Quality of Care Will Go Down”
This objection rests on the assumption that the current US system delivers high-quality care that would be degraded under a public system. The evidence does not support that premise.
The most comprehensive multi-country healthcare performance study — the Commonwealth Fund’s Mirror Mirror 2024 report, synthesizing 72 indicators across five domains for eleven high-income nations — ranked the United States last overall. The US ranked last in four of the five domains, including health care outcomes, which is the most important domain.
US life expectancy in 2024 was 79.0 years, compared to a comparable-country average of 82.7 years — a gap of 3.7 years. The United States spends approximately $13,432 per person annually on healthcare, nearly twice the OECD high-income country average, and ranks 32nd among 38 OECD nations in infant mortality.
Research on mortality amenable to healthcare — deaths that should not occur with timely and effective care — shows single-payer systems averaging approximately 70 deaths per 100,000, compared to 112 per 100,000 in the United States.
The quality objection is not without any foundation. There are specific areas where US care is excellent — certain cancer survival rates, access to specialty procedures for insured patients, pharmaceutical innovation. These are real strengths of the current system. The question is whether those strengths, concentrated among the well-insured, constitute overall system quality when measured against outcomes across the entire population.
Verdict: The evidence does not support the premise that the US currently delivers superior quality outcomes. On population-level measures the US consistently ranks last or near last among comparable nations at significantly higher cost. The quality objection requires specifying quality for whom.
Objection 4: “Americans Like Their Private Insurance”
Survey data on this question is more nuanced than the objection suggests.
It is true that many Americans express satisfaction with their own health plan in the abstract. It is also true that satisfaction changes significantly when insurance is actually used. Research consistently finds that prior authorization delays, claim denials, surprise bills, and out-of-pocket costs that exceed expectations produce substantially lower satisfaction than the initial response suggests.
The American Medical Association’s 2025 Prior Authorization Physician Survey — a survey of 1,000 physicians — found that 95% of physicians report that prior authorization delays access to necessary care, 79% report that patients abandon treatment due to authorization challenges, and 26% report that prior authorization led to a serious adverse event including hospitalization, permanent impairment, or death. More than 45% of insured adults have received a bill for a service they believed insurance should have covered.
Comparative satisfaction data is also relevant. When consumer satisfaction with private health insurance is compared to satisfaction with government-operated programs — Medicare, Medicaid, and the VA — government programs are preferred not only for services provided but for cost to the consumer.
Verdict: The objection overstates the case. Satisfaction with private insurance in the abstract does not reflect satisfaction with private insurance in practice. When consumers interact with the prior authorization system, the claims process, and surprise billing, satisfaction drops substantially. Government-operated programs consistently rate higher than private insurance in comparative surveys.
Objection 5: “It Would Destroy the Insurance Industry and Kill Jobs”
This objection raises a legitimate transition concern but does not constitute a policy argument against the system itself.
The US health insurance industry employs approximately 500,000 people in health insurance specifically. Under single-payer that employment base would be substantially disrupted. This is a real and serious consequence that transition planning must address.
The Sanders bill includes a transition fund and retraining provisions specifically designed to address workforce displacement. Other countries that have transitioned to universal systems have managed similar displacement through comparable mechanisms.
There is also a countervailing consideration. Administrative simplification under single-payer eliminates a significant share of current healthcare administrative work — the personnel whose entire function is navigating billing, claims, prior authorization, and denial management across hundreds of plans. Many of those workers have skills directly transferable to healthcare administration in a simplified system. The administrative savings of approximately $500 billion annually identified by the Congressional Budget Office represent labor currently employed in work that generates no patient care.
Verdict: The transition concern is legitimate and requires serious policy attention. It is not a policy argument against single-payer as a system. Every major technological and social transition displaces incumbent employment. Policy design can address the transition; it cannot use the transition as a reason to preserve a harmful system permanently.
Prior Authorization: A Dedicated Examination
Prior authorization deserves separate treatment because it represents the most relatable and most documented failure of the current insurance system — and the one most directly eliminated by single-payer.
Prior authorization is the requirement that physicians obtain insurance company approval before providing treatments they have already determined are medically necessary. The AMA’s 2025 Prior Authorization Physician Survey documents its scope:
Physicians submit an average of 43 prior authorization requests per week. They spend an average of 16 hours per week on the process — the equivalent of two full working days. Of the 1,000 physicians surveyed, 95% report that prior authorization delays access to necessary care, 79% report patients abandon treatment due to authorization challenges, 92% report that it negatively affects clinical outcomes, and 89% report that it contributes to physician burnout.
The most significant data point in the survey concerns what happens when denials are appealed. Among prior authorization denials that were appealed, 81.7% were fully or partially overturned on appeal. More than four out of five challenged denials were reversed.
This figure requires careful interpretation. It does not mean that 81.7% of all prior authorization requests are eventually approved — most denials are never appealed. It means that when someone has the time, knowledge, and resources to challenge a denial, they succeed more than four times out of five. The research question this raises is what distinguishes the denial from the appeal, and whether the initial denial was primarily a medical judgment or primarily a cost-management strategy.
A 2025 RAND Corporation commentary on prior authorization documented specific cases: a child with newly diagnosed Type 1 diabetes held in the hospital while awaiting approval for generic insulin; a critically ill infant in respiratory distress denied admission because a non-indicated medication had not been administered. These are cases from a single commentary by a nonpartisan research institution.
In June 2025, 60 health insurers pledged to streamline prior authorization requirements. Among the physicians surveyed by the AMA, only one in three believed the pledge would produce meaningful improvement. A comparable pledge in 2018 produced little measurable progress.
Under single-payer, prior authorization for basic covered services is eliminated. The government as payer sets coverage rules. Physicians prescribe within those rules. The 16 weekly hours of administrative burden and the 43 weekly requests disappear from physician practice.
The Public Option: A Separate Examination
The public option — adding a government-run insurance plan to compete in the marketplace alongside private insurers — is frequently proposed as an alternative to single-payer that achieves similar goals with less disruption. The evidence from states that have implemented public options warrants examination.
Washington State launched the country’s first public option in 2021. Many hospitals declined to participate due to financial concerns about lower reimbursement rates. As of the available reporting period, enrollment reached fewer than 3% of marketplace participants.
Colorado implemented a requirement that insurers reduce premiums by 5% per year for three years. As of 2023, only one insurer had met the reduction goals.
The structural argument against public option effectiveness centers on adverse selection. Private insurers operating in the same marketplace as a public option have incentives to attract lower-risk enrollees — those who do not expect to need much care — while the public option accepts all applicants. If the population accepting the public option skews toward higher-cost patients, its premiums rise while private insurer premiums fall, potentially accelerating toward a two-tier system rather than universal coverage.
A second structural concern is administrative. A public option leaves the existing insurance industry in place, maintaining the administrative complexity — the hundreds of plans, the billing variation, the denial infrastructure — that generates most of the estimated $500 billion in annual administrative waste. The savings from a public option are necessarily smaller than the savings from a single payer.
Proponents of the public option argue that it offers a more politically achievable path toward broader coverage, that it allows the market to demonstrate the value of a public plan, and that administrative savings, while smaller than single-payer, are still meaningful. These are serious arguments that the evidence does not fully resolve.
Verdict: The public option addresses some coverage gaps. The evidence from state implementation suggests it does not fundamentally restructure the insurance market or capture the administrative savings that make single-payer financially distinctive. Whether it is a step toward single-payer or an alternative to it is a genuinely contested question.
The Government Already Runs Healthcare at Scale
One argument in the single-payer debate that receives less attention than it deserves is that the US federal government already operates two large healthcare systems serving millions of Americans.
The Military Health System operates with a budget exceeding $50 billion annually and serves approximately 9.5 million beneficiaries through 51 hospitals, 424 clinics, 248 dental clinics, and 251 veterinary facilities. TRICARE, the government healthcare benefit for active military members, retirees, and their families, provides coverage automatically upon qualification with no underwriting, no exclusions for pre-existing conditions, and no out-of-pocket fees at Military Treatment Facilities under TRICARE Prime. Research on TRICARE has found improved patient outcomes including reduced hospitalizations and improved patient satisfaction.
The VA Health Care System serves the nation’s veterans. Its Patient Aligned Care Teams program has been associated with improved patient outcomes and increased patient satisfaction. Its telehealth program has expanded access to care in rural and remote communities.
These systems are not without documented problems. VA wait times have been a significant policy issue, particularly following the 2014 scandals involving falsified scheduling records. Underfunding has created capacity constraints in specific periods. These are real and documented failures.
The policy question raised by these systems is whether their failures indicate that government cannot effectively deliver healthcare, or whether they indicate that government healthcare systems degrade when governments choose to underfund them. The evidence from TRICARE — which is consistently funded and consistently performs well — and from the VA in adequately funded periods suggests the latter interpretation. The same question applies to international comparisons: the NHS degraded under sustained austerity; Taiwan’s NHI, adequately funded since its launch, ranks first globally.
Verdict: The existence of well-functioning government healthcare programs serving millions of Americans complicates the argument that government cannot run healthcare. The failures of programs like the VA are better explained by funding decisions than by the inherent incapacity of government as a healthcare administrator.
Summary of Verdicts
| Objection | Verdict |
|---|---|
| It will raise my taxes | Misleading as a general claim; valid for high earners when the full cost comparison is made |
| You’ll wait forever | Real in underfunded systems; not an inherent feature of single-payer; incomplete without counting uninsured Americans |
| Quality will go down | US currently ranks last among high-income nations on health outcomes; premise is not supported by evidence |
| Americans like their insurance | Overstated; satisfaction with insurance in practice is substantially lower than in the abstract |
| It will kill jobs | Legitimate transition concern; not a policy argument against the system |
| Prior authorization | Documented source of harm; 81.7% appeal reversal rate raises serious questions about denial as medical judgment |
| Public option | Addresses some coverage gaps; does not capture the administrative savings or structural change of single-payer |
| Government can’t run healthcare | Two large government systems currently operate; failures are better explained by funding than by inherent government incapacity |
Sources
Medicare for All Act of 2025, Sanders bill text and summary.
RAND Corporation / JAMA Network: Study on Medicare for All financing progressivity and distributional effects.
Citizens for Tax Justice: Analysis of Medicare for All net cost by income level.
American Medical Association: 2025 Prior Authorization Physician Survey (1,000 physicians).
RAND Corporation: Commentary on prior authorization patient harm, 2025.
Johns Hopkins Medicine: Research on prior authorization and patient harm, 2025.
Commonwealth Fund: Mirror Mirror 2024 international healthcare system performance comparison.
KFF: 2025 Employer Health Benefits Survey, worker premium contribution data.
Congressional Budget Office: Estimate of administrative cost savings under single-payer.
National Academy for State Health Policy: Public option implementation tracking, Washington State and Colorado.
StatPearls / military health literature: TRICARE and VA healthcare comparison and outcomes data.
MedPAC: Data on Medicare Advantage prior authorization rates and outcomes.
OECD: Health statistics 2024–2025, life expectancy and infant mortality by country.
Centers for Disease Control and Prevention: US life expectancy data, 2024.
The Complete Single Payer Healthcare Series
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.